Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 5/20 | 0.51 |
| ▸ | MMP8 | P22894 | 4/20 | 0.51 |
| ▸ | MMP9 | P14780 | 3/20 | 0.51 |
| ▸ | MMP1 | P03956 | 4/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 5/20 | 0.43 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | CTRC | Q99895 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1258248 | 0.85 | PPARG (0.44) | MMP3MMP8MMP9MMP1PPARG | |
| SCHEMBL1258247 | 0.85 | PPARG (0.44) | MMP3MMP8MMP9MMP1PPARG | |
| SCHEMBL7797270 | 0.85 | CYP2D6 (0.49) | MMP3MMP8MMP9MMP1 | |
| SCHEMBL11019274 | 0.81 | PPARG (0.55) | PPARGPPARACTRC | |
| SCHEMBL10849403 | 0.76 | PPARG (0.56) | PPARGPPARACTRC | |
| SCHEMBL7787613 | 0.76 | HDAC2 (0.43) | HDAC2SMN1; SMN2PPARGPPARA | |
| SCHEMBL1258303 | 0.75 | CYP2D6 (0.53) | — | |
| SCHEMBL1258301 | 0.75 | CYP2D6 (0.53) | — | |
| SCHEMBL9614318 | 0.74 | PPARG (0.59) | PPARGPPARACTRC | |
| SCHEMBL8879002 | 0.74 | MMP3 (0.49) | MMP3MMP8MMP9MMP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879911-B2 | 2-(4-Fluorophenoxy-N-hydroxyacetamide where the \"oxy\" can also be sulfonyl, sulfamyl or sulfinyl; enzyme inhibitors of the \"lethal factor\" enzyme released by bacillus anthraci that splits an essential peptide needed by mammals for signal transmission; antidotes; biological warfare | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-01 | — | — | US | disclosed |
| US-20080188565-A1 | Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188565-A1 | Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning | ANTXR2, HAAO, PAOX | MMP3 1146/4885MMP8 589/4885MMP9 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.